Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
October 29, 2025 | HEOR, ISPOR Europe, Market Access, Pricing, US policy, access and pricing, ispor, isporeurope, mfn, most-favoured nation, reimbursement
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10 poster presentations, and the opportunity to try EVID AI, a fast track to literature-based research and evidence synthesis.
With a drinks reception at 5pm on the Monday, the opportunity to grab a free Scottish-themed minifigure, and experts available at the booth at all times, the company warmly invites all attendees to stop by booth 212 for a chat.
HEOR THEATER
MFN Pricing: “More Fun to Navigate” – A European Roadmap to Success
At 12.15pm in Theater 1 on Tuesday 11th November, Tim Wright, EVP, Access & Pricing, Genesis Research Group, will be delivering a presentation on most favored nation (MFN) pricing. Anyone responsible for pricing, market access, early commercial strategy, policy, or HEOR, will find great value in the content.
Most-Favored Nation (MFN) pricing is characterized by uncertainty, particularly regarding how the Administration will steer it through Congress. However, we cannot wait for the legislative process to complete—doing nothing is not an option. Tim Wright, EVP at Genesis Research Group, with 30 years of in-house and consulting experience, will provide a practical walk-through on how to plan for success, including key milestones and challenges along the way.
During the session, Tim will cover essential steps in establishing the US anchor price, including the role of value-based pricing, the importance of setting an early economically justifiable price, and the pros and cons of different US price options. He will then “fly across the Atlantic” to show how these planning steps can positively influence European strategic pricing and, importantly, what options manufacturers have to minimize price erosion risks from subsequent approvals.
By the end of the session, attendees will have:
- A roadmap to help guide them
- through the uncharted territory of Most-Favored Nation pricing.
- A clear understanding of the implications for both biotechs and large pharma.
TRY EVID AI FOR YOURSELF!
Genesis Research Group will also be providing visitors to its booth the opportunity to try EVID AI for themselves. EVID AI is an AI-powered platform for finding, reviewing, and understanding literature-based evidence. If you have too many questions and not enough time, EVID AI allows you to quickly find the most relevant literature, receive AI-generated research summaries, and access to reliable, up-to-date sources.
Visitors will be able to give the platform a try by themselves or they can ask one of Genesis’s evidence synthesis experts for a guided tour.
GRAB A FREE MINIFIGURE!
Visit booth 212 to secure a free minifigure, custom-designed for ISPOR Europe! Choose from a variety of skin tones, hair and facial expressions.
10 SCIENTIFIC CONTRIBUTIONS
Genesis Research Group is proud to have contributed to 10 posters to the conference, including two posters recognized by ISPOR EU as among the top 5% of submissions. See the timetable below or visit ISPOR Europe’s website for full details.
DRINKS RECEPTION
Attendees will also be able to connect with the Genesis Research Group team on an informal basis. Complimentary drinks and canapés will be served from 5pm on Monday 10th November.
Schedule a meeting with the Genesis team
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a 'deep dive' into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights...
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...